secwatch.observer — SEC 8-K summary
======================================

Issuer:     NANOVIRICIDES, INC. (NNVC)
CIK:        0001379006
Form:       8-K
Filed at:   2021-09-21T23:59:59+00:00
Accession:  0001104659-21-117728
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study
--------------------------------------------------------------------------------

- Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
- After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.
- NV-CoV-2-R combines nanoviricides platform attack on virus outside cells with remdesivir inside cells.
- Company expects improved pan-coronavirus activity retaining effectiveness against emerging variants.
- Draft data inadvertently published; final press release expected by September 28, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/0001104659-21-117728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/tm2128140d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-117728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer